Nuveen Asset Management LLC Buys 50,379 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Nuveen Asset Management LLC boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 524,579 shares of the biotechnology company's stock after purchasing an additional 50,379 shares during the quarter. Nuveen Asset Management LLC owned 0.55% of Sarepta Therapeutics worth $63,784,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. LMR Partners LLP grew its holdings in Sarepta Therapeutics by 173.4% during the fourth quarter. LMR Partners LLP now owns 3,724 shares of the biotechnology company's stock valued at $453,000 after purchasing an additional 8,797 shares during the period. Logan Capital Management Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $61,000. Lighthouse Investment Partners LLC grew its holdings in Sarepta Therapeutics by 112.9% during the fourth quarter. Lighthouse Investment Partners LLC now owns 2,446 shares of the biotechnology company's stock valued at $297,000 after purchasing an additional 21,446 shares during the period. J. Goldman & Co LP grew its holdings in Sarepta Therapeutics by 10.9% during the fourth quarter. J. Goldman & Co LP now owns 87,866 shares of the biotechnology company's stock valued at $10,684,000 after purchasing an additional 8,628 shares during the period. Finally, Guardian Wealth Advisors LLC NC acquired a new position in Sarepta Therapeutics during the fourth quarter valued at approximately $244,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Down 2.3%

SRPT traded down $0.89 during trading hours on Friday, hitting $37.90. 2,048,795 shares of the company's stock were exchanged, compared to its average volume of 1,787,371. Sarepta Therapeutics, Inc. has a 1-year low of $34.10 and a 1-year high of $173.25. The stock's 50-day moving average is $54.60 and its two-hundred day moving average is $94.39. The stock has a market cap of $3.72 billion, a price-to-earnings ratio of 30.32 and a beta of 0.85. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same period last year, the company posted $0.73 earnings per share. The business's revenue was up 80.2% compared to the same quarter last year. Sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 7.70% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SRPT. Needham & Company LLC decreased their price objective on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Evercore ISI cut shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price target for the company. in a report on Thursday, May 8th. Cantor Fitzgerald reduced their price target on shares of Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. UBS Group reduced their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.